Waters Corporation Earnings Expectations
Waters Corporation (NYSE: WAT) is gearing up to reveal its quarterly earnings report on a significant date. Investors are keen to understand what this announcement may hold for them and how it could potentially influence the stock's performance.
Analysts project that Waters is set to announce an earnings per share (EPS) of approximately $2.68. This anticipated figure has stirred excitement among investors who are hoping for not only a positive earnings surprise but also a constructive outlook for the upcoming quarter.
Understanding Historical Earnings Performance
In the last reporting period, Waters managed to surpass EPS estimates by $0.07, which catalyzed a notable 4.83% hike in its share price on the subsequent trading day. Observing these patterns can provide insights into market reactions following earnings releases.
A detailed examination of Waters’s prior quarterly earnings reveals fluctuations in EPS estimates and actual results, along with the corresponding price changes:
Here’s a breakdown showcasing past performance metrics:
Waters Corporation Share Price Analysis
As of a recent date, Waters shares were trading at $326.59, reflecting a commendable increase of 24.59% over the last year. Such growth suggests a generally optimistic sentiment from long-term shareholders as they approach the earnings announcement.
Analysts' Insights on Waters Corporation
Investors must pay close attention to market sentiment and expectation trends that can significantly impact stock behavior. Recent evaluations of Waters Corporation have highlighted the overall consensus from analysts who have provided ratings.
The consensus among analysts rates Waters as a Buy, with an optimistic average target price for the next year set at $365.00. This projection suggests a favorable outlook of approximately 11.76% upside potential for stakeholders.
Comparative Peer Ratings Overview
In a broader industry context, reviewing the analyst ratings and expected price targets for comparable companies can offer valuable insights. This analysis includes notable competitors such as Avantor, Illumina, and Revvity, providing a well-rounded view of market dynamics.
- Avantor is under an Outperform rating, with an average price target suggesting a potential downside of 91.22%.
- Illumina, meanwhile, is currently rated Neutral, with projections indicating a possible downside of 48.74%.
- Revvity attracts an Outperform rating, with an average one-year price target suggesting an expected downside of about 58.66%.
Peer Metrics Overview
The comparative metrics among Avantor, Illumina, and Revvity reveal key standings within the industry and shed light on their respective performance against Waters:
Company Metrics Summary:
Company | Consensus | Revenue Growth | Gross Profit | Return on Equity
Waters | Buy | -4.33% | $420.29M | 10.70%
Avantor | Outperform | -2.36% | $581.50M | 1.73%
Illumina | Neutral | -5.44% | $721M | -55.45%
Revvity | Outperform | -2.45% | $385.51M | 0.70%
Waters stands out with the highest Gross Profit and Return on Equity figures, yet trails in Revenue Growth when compared to its peers.
Exploring Waters Corporation's Offerings
Waters specializes in providing essential tools such as liquid chromatography, mass spectrometry, and thermal analysis equipment. These instruments offer crucial insights into molecular structures and physical properties, enabling clients to improve health and well-being. As of recent sales data, Waters appears to have attracted substantial clientele in the biopharmaceutical sector, accounting for 57% of its sales, followed by 31% from industrial clients, and 12% within academia and government sectors.
Diving into Waters's Financial Performance
Market Capitalization: Waters operates with a market capitalization that suggests challenges relative to industry peers.
Revenue Growth: A difficult few months culminated in a reported revenue decline of about -4.33% as of the close of June 2024, indicating a shortfall in revenue performance compared to competitors in the Health Care sector.
Net Margin: Despite the challenges in growth, Waters boasts a robust net margin of 20.15%, showcasing effective cost management and strong profitability.
Return on Equity (ROE): The company maintains an impressive 10.7% ROE, suggesting effective use of shareholder equity.
Return on Assets (ROA): With a notable ROA of 3.19%, Waters demonstrates effective asset management in achieving financial success.
Debt Management: The company's debt-to-equity ratio of 1.48 raises concerns regarding its reliance on borrowed funds, juxtaposed against industry norms.
Frequently Asked Questions
What is the expected EPS for Waters Corporation?
The anticipated EPS for Waters Corporation is $2.68.
How did Waters perform in previous earnings quarters?
In the last quarter, Waters surpassed EPS estimates by $0.07, triggering a 4.83% rise in share price following the announcement.
What is the current share price trend for Waters Corporation?
As of late October, shares were trading at $326.59, reflecting an increase of 24.59% over the previous year.
What are analysts saying about Waters Corporation?
Analysts have given Waters a consensus rating of Buy with a one-year target price of $365.00, indicating an upside potential of 11.76%.
In which sectors does Waters operate?
Waters primarily serves biopharmaceutical clients, alongside industrial and academic/government sectors.
